Particularly, a recent network meta-analysis has reported that GLP-1 RAs inhibited the risk of stroke than SGLT-2 inhibitors, although the risk of cardiovascular death and myocardial infarction is comparable30. Here, SLC5A2 is linked to stroke disorder.